TG Therapeutics, Inc. (TGTX) SEC Filings & Earnings Calls

Increased R&D spending

“Other research and development expense was $87.3 million for the three months ended June 30, 2026, as compared to $27.5 million during the three months ended June 30, 2025.” · word for word

Increased SG&A spending

“Other selling, general and administrative expenses totaled $62.3 million for the three months ended June 30, 2026, as compared to $43.5 million during the comparable period ended June 30, 2025.” · word for word

High debt level

“Loan payable – non-current 745,387 245,645” · word for word

Customer concentration

“Customer 1 40 % 42 %” · word for word

Tariff exposure

“The United States and other countries have recently imposed, and may continue to impose, new tariffs. Tariffs are an inventoriable cost, and the Company’s sole supplier of bulk drug substance is located outside of the U.S.” · word for word

High R&D spend due to pipeline investments, including subcutaneous manufacturing costs.

“R&D expense increased to $95.3M from $31.8M, driven by subcutaneous manufacturing and clinical trials.”

Dependence on single product BRIUMVI for revenue.

“BRIUMVI represents the vast majority of product revenue.”

Customer concentration risk

“Customer 1 42%, Customer 2 27%, Customer 3 20% of gross product revenue for Q1 2026”

Extended payment terms on accounts receivable

“extended payment terms have been offered during the BRIUMVI commercial launch” · word for word

Concentration on BRIUMVI revenue

“BRIUMVI U.S. net product revenue of $594.1 million for the full year of 2025, representing approximately 92% growth year over year.” · word for word

CEO succession risk

“Mr. Weiss has served as TG’s Chairman, President and CEO since December 2011.”

Dependence on key personnel

“Continuity of experienced leadership has also been an important factor in our performance, with both of our NEOs having served in their roles since December 2011.” · word for word

Regulatory and clinical development risk

“Achieve certain regulatory goals for BRIUMVI and pipeline products; Commencement of clinical programs; Enrollment goals tied to ongoing clinical programs” · word for word

Drug supply and manufacturing risk

“Ensure sufficient and continued supply of BRIUMVI; Ensure no critical regulatory or quality observations; Make defined progress on clinical pipeline manufacturing goals” · word for word

Debt service obligations

“Scheduled quarterly amortization payments of $37.5 million starting Q1 2030.”

R&D tax capitalization uncertainty

“The OBBBA reinstates the option to deduct domestic research and development expenditures in the year incurred, commencing with tax years beginning after December 31, 2024.” · word for word

Dependence on BRIUMVI for revenue; pipeline and regulatory risks for new indications.

“BRIUMVI is primary revenue driver; pipeline milestones subject to clinical and regulatory outcomes.”

Operating expense increase for subcutaneous manufacturing and secondary start-up costs.

“approximately $100 million in expenses associated with the subcutaneous BRIUMVI manufacturing costs and secondary manufacturer start-up costs” · word for word

Dependence on BRIUMVI for revenue; pipeline and regulatory risks for new indications and formulations

“Pipeline milestones subject to clinical trial success and regulatory approval; single product revenue concentration”

Customer concentration risk

“Customer 1 represents 47% of gross product revenue for Q3 2025”

Cash burn and share repurchase risk

“Cash and cash equivalents decreased from $179.9M to $74.1M; treasury stock purchases of $78.2M in Q3”

Dependence on single product

“Product revenue entirely from BRIUMVI”

Dependence on single product BRIUMVI for revenue concentration risk.

“Product revenue, net consists primarily of net product sales of BRIUMVI in the United States.” · word for word